Delap Wealth Advisory LLC Purchases New Position in Natera, Inc. (NASDAQ:NTRA)

Delap Wealth Advisory LLC purchased a new stake in shares of Natera, Inc. (NASDAQ:NTRA) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 4,190 shares of the medical research company’s stock, valued at approximately $454,000.

Several other institutional investors also recently bought and sold shares of the stock. Itau Unibanco Holding S.A. purchased a new position in Natera during the second quarter worth approximately $28,000. GAMMA Investing LLC grew its stake in Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 108 shares during the period. YHB Investment Advisors Inc. purchased a new stake in Natera in the 1st quarter worth $36,000. Principal Securities Inc. acquired a new position in Natera during the fourth quarter worth $32,000. Finally, Tobam acquired a new position in Natera during the second quarter worth $74,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Stock Performance

Shares of Natera stock opened at $127.78 on Friday. The business’s fifty day simple moving average is $114.45 and its 200-day simple moving average is $105.43. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The firm has a market cap of $15.69 billion, a PE ratio of -40.96 and a beta of 1.53. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $132.01.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.39. The company had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. Natera’s revenue was up 58.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.97) earnings per share. Equities analysts forecast that Natera, Inc. will post -1.96 earnings per share for the current year.

Insider Activity at Natera

In related news, insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total value of $344,439.00. Following the completion of the sale, the insider now owns 284,741 shares in the company, valued at approximately $36,324,409.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Natera news, CEO Steven Leonard Chapman sold 37,500 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $108.10, for a total value of $4,053,750.00. Following the completion of the transaction, the chief executive officer now owns 213,351 shares in the company, valued at $23,063,243.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jonathan Sheena sold 2,700 shares of the company’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $127.57, for a total value of $344,439.00. Following the sale, the insider now directly owns 284,741 shares in the company, valued at approximately $36,324,409.37. The disclosure for this sale can be found here. In the last quarter, insiders sold 93,921 shares of company stock worth $10,551,281. Insiders own 7.60% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of research reports. StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research note on Wednesday, August 28th. UBS Group cut their price objective on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Canaccord Genuity Group lifted their price target on Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Robert W. Baird increased their price objective on Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Finally, Morgan Stanley raised their price objective on Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $120.07.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.